Iressa — Competitive Intelligence Brief

Iressa (gefitinib) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Kinase Inhibitor [EPC]. Area: Oncology.

marketed Kinase Inhibitor [EPC] Epidermal growth factor receptor Oncology

Target snapshot

Iressa (gefitinib) — Pfizer Inc.. Iressa blocks the epidermal growth factor receptor (EGFR) signaling pathway, preventing cancer cell growth and proliferation.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Iressa TARGET	gefitinib	Pfizer Inc.	marketed	Kinase Inhibitor [EPC]	Epidermal growth factor receptor	2003-01-01
Vizimpro	dacomitinib	Pfizer	marketed		Epidermal growth factor receptor	2018-01-01
Portrazza	NECITUMUMAB	Eli Lilly Co	marketed	Epidermal Growth Factor Receptor Antagonist [EPC]	Epidermal growth factor receptor	2015-01-01
Gilotrif	afatinib	Boehringer Ingelheim	marketed	Kinase Inhibitor [EPC]	Epidermal growth factor receptor	2013-01-01
Tykerb	LAPATINIB	Novartis	marketed	Kinase Inhibitor	Epidermal growth factor receptor	2007-01-01
Tarceva	erlotinib	Osi Pharms	marketed	Kinase Inhibitor	Epidermal growth factor receptor	2004-01-01
Erbitux	cetuximab	Imclone	marketed	Epidermal Growth Factor Receptor Antagonist [EPC]	Epidermal growth factor receptor	2004-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Kinase Inhibitor [EPC] class)

1. · 12 drugs in this class
2. Pfizer · 7 drugs in this class
3. Novartis · 3 drugs in this class
4. Bayer · 2 drugs in this class
5. Boehringer Ingelheim · 2 drugs in this class
6. AstraZeneca · 2 drugs in this class
7. Beigene Usa Inc · 1 drug in this class
8. BeiGene · 1 drug in this class
9. AbbVie · 1 drug in this class
10. Bristol · 1 drug in this class